There has been a dizzying amount of information lately about using prostate-specific antigen (PSA) testing to screen for prostate cancer.

Metastasis of an aggressive cancer is difficult to treat, especially when the cancer is already resistant to most therapies, as in castration-resistant prostate cancer.

Having a clinical trial canceled is a nightmare for researchers.  If the trial stops, researchers want it to be like this.

The use of robotic-assisted surgery is only a few years old, and some surgeons have taken a real shine to having a previously unknown level of precision and control during an operation.

Recent genetic studies on prostate cancer have found an entirely new variation that does not follow the normal pattern and could represent an entirely different sort of cancer.

Not only is prostate cancer tough, the toll it takes on sexual function doesn’t make things any easier. A little support from peers and professionals can help.

Scientists have piles of data showing that people simply don't understand or care about statistics.  Most people find numbers un-intuitive.

Following a period of public discussion, the final official recommendation has been made to stop using the PSA test to screen for prostate cancer.

For historical reasons that are sometimes still valid, some people are not comfortable disclosing everything to a health professional, or even trusting them to tell them the truth.

The current most widely used test for detecting and monitoring prostate cancer, known as prostate specific antigen (PSA), has a lot of room for improvement for detecting new cancers.